Aditxt, Inc. is a commercial-stage biotechnology company developing products across immune health, precision health, population health, women's health, and neurologic health. The company's primary offerings include AditxtScore, a diagnostic tool designed to help individuals assess and monitor their immune profiles to inform management of immune-related conditions, and Apoptotic DNA Immunotherapy, a nucleic acid-based platform that aims to induce immune tolerance. The company is also developing ADI-100 for clinical applications including skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt maintains licensing agreements with Loma Linda University and Stanford University to support its research and development efforts.
The company operates as a Delaware corporation with headquarters in Mountain View, California. Aditxt employs 26 full-time employees and operates at a small scale typical of early-stage biotechnology firms. The company was incorporated in 2017 and rebranded from ADiTx Therapeutics, Inc. to Aditxt, Inc. in July 2021. Aditxt trades on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-3062.51 | $-3062.51 | -2731.7% | |
| 2023 | $-108.15 | $-108.15 | -626.3% | |
| 2022 | $-14.89 | $-14.89 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |